Cargando…

Investigating the Heterogeneity of Immune Cells in Triple-Negative Breast Cancer at the Single-Cell Level before and after Paclitaxel Chemotherapy

Despite the numerous treatments for triple-negative breast cancer (TNBC), chemotherapy is still one of the most effective methods. However, the impact of chemotherapy on immune cells is not yet clear. Therefore, this study aims to explore the different roles of immune cells and their relationship wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Heng, Lin, Zhang, Zhang, Yangfan, Liu, Jingjing, Chen, Qi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532302/ https://www.ncbi.nlm.nih.gov/pubmed/37762493 http://dx.doi.org/10.3390/ijms241814188

Ejemplares similares

A Novel Paclitaxel Derivative for Triple-Negative Breast Cancer Chemotherapy
por: Liu, Yuetong, et al.
Publicado: (2023)

Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy
por: Di Cosimo, Serena, et al.
Publicado: (2019)

Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin
por: Wang, Ruo-Xi, et al.
Publicado: (2016)

Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
por: Li, Qing, et al.
Publicado: (2020)

Morphine counteracts the effects of paclitaxel in triple-negative breast cancer cells
por: Sezer, Gülay, et al.
Publicado: (2022)

Methylseleninic Acid Enhances Paclitaxel Efficacy for the Treatment of Triple-Negative Breast Cancer
por: Qi, Yanfeng, et al.
Publicado: (2012)

Evaluation of triple negative breast cancer with heterogeneous immune infiltration
por: Quintana, Ángela, et al.
Publicado: (2023)

Preparation and anti-triple-negative breast cancer cell effect of a nanoparticle for the codelivery of paclitaxel and gemcitabine
por: Yang, Fan, et al.
Publicado: (2023)

Molecular heterogeneity in adjacent cells in triple-negative breast cancer
por: Huebschman, Michael L, et al.
Publicado: (2015)

Heterogeneity at the invasion front of triple negative breast cancer cells
por: Aw Yong, Koh Meng, et al.
Publicado: (2020)

Immune Cell Infiltration-Based Characterization of Triple-Negative Breast Cancer Predicts Prognosis and Chemotherapy Response Markers
por: Lv, Yufei, et al.
Publicado: (2021)

Effect of Ect2 Expression on the Growth of Triple-Negative Breast Cancer Cells with Paclitaxel Intervention
por: Wang, Hongkun, et al.
Publicado: (2020)

Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer
por: Huang, Liang, et al.
Publicado: (2017)

Atractylenolide-I Sensitizes Triple-Negative Breast Cancer Cells to Paclitaxel by Blocking CTGF Expression and Fibroblast Activation
por: Wang, Meng, et al.
Publicado: (2021)

Circulating immune cell dynamics in patients with triple negative breast cancer treated with neoadjuvant chemotherapy
por: Talamantes, Sarah, et al.
Publicado: (2020)

Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer
por: Tan, Antoinette R., et al.
Publicado: (2023)

Transcytosable Peptide-Paclitaxel Prodrug Nanoparticle for Targeted Treatment of Triple-Negative Breast Cancer
por: Wang, Longkun, et al.
Publicado: (2023)

Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
por: Ghallab, Ahmed
Publicado: (2020)

Single-Cell RNA-Seq Reveals Heterogeneous lncRNA Expression in Xenografted Triple-Negative Breast Cancer Cells
por: Pinkney, Holly R., et al.
Publicado: (2021)

Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel–cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines
por: Ye, Jun, et al.
Publicado: (2016)

TGF-β-Induced TMEPAI Attenuates the Response of Triple-Negative Breast Cancer Cells to Doxorubicin and Paclitaxel
por: Wardhani, Bantari WK, et al.
Publicado: (2020)

Eribulin and Paclitaxel Differentially Alter Extracellular Vesicles and Their Cargo from Triple-Negative Breast Cancer Cells
por: Pederson, Petra J., et al.
Publicado: (2021)

Efficiency of Cytokine-Induced Killer Cells in Combination with Chemotherapy for Triple-Negative Breast Cancer
por: Li, Man, et al.
Publicado: (2018)

CLDN1 Sensitizes Triple-Negative Breast Cancer Cells to Chemotherapy
por: Lemesle, Marine, et al.
Publicado: (2022)

Immune-related biomarkers in triple-negative breast cancer
por: Zhang, Juan, et al.
Publicado: (2021)

Weekly vs Every-3-Week Carboplatin with Weekly Paclitaxel in Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Retrospective Analysis
por: Landry, Kara K, et al.
Publicado: (2022)

Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study
por: Liu, Yin, et al.
Publicado: (2022)

Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial
por: Wang, Chengzheng, et al.
Publicado: (2023)

Decoding Immune Heterogeneity of Triple Negative Breast Cancer and Its Association with Systemic Inflammation
por: Romero-Cordoba, Sandra, et al.
Publicado: (2019)

A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer
por: Wu, Xiaoqiu, et al.
Publicado: (2020)

Single-cell RNA-seq dissects the intratumoral heterogeneity of triple-negative breast cancer based on gene regulatory networks
por: Zhou, Shunheng, et al.
Publicado: (2021)

Knockdown of SERPINE1 reverses resistance of triple-negative breast cancer to paclitaxel via suppression of VEGFA
por: Zhang, Qian, et al.
Publicado: (2020)

Metronomic chemotherapy for triple negative breast cancer?
por: Di Desidero, Teresa, et al.
Publicado: (2016)

BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers
por: Blanchard, Zannel, et al.
Publicado: (2015)

Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study
por: Arpino, Grazia, et al.
Publicado: (2015)

Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation
por: Dieci, Maria Vittoria, et al.
Publicado: (2022)

Self-Assembly Engineering Nanodrugs Composed of Paclitaxel and Curcumin for the Combined Treatment of Triple Negative Breast Cancer
por: Zuo, Shuting, et al.
Publicado: (2021)

Study on the thermal stability of nab-paclitaxel during hyperthermic intraperitoneal chemotherapy
por: Zhang, Jingjing, et al.
Publicado: (2023)

Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial
por: Zhang, Pin, et al.
Publicado: (2016)

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study
por: Shao, Zhiying, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_fhsnlknrlcte1mdc00902d7cjo